Background Image


January 8, 2019

Apptomics' Clinically Validated Digital Platform E.V.A Completes First Sub-Study for Essential Tremor

In Partnership with BBK Worldwide and Biotaware, Apptomics is working to Evolve the Digital Platform to Become the Standard for Monitoring Movement Disorders

Apptomics, Inc., an innovator of digital solutions for optimized neurological care, announces that the digital platform E.V.A (Evaluation. Validation. Action) has successfully been used in a study for essential tremor. This marks a major milestone for the company as the platform already has extensive clinical validation in Parkinson's disease and is currently used in clinical trials for Parkinson's disease. E.V.A is a digital therapeutic platform designed to detect and quantify differences in motor performance for patients with chronic movement disorders, providing doctors with objective data to optimize medical treatment and improve outcomes. Recent enhancements to the platform include the addition of a digital spirography, a functional test of upper limb function used to objectively quantify tremor severity.

Read More
January 8, 2019

Apptomics aims to establish its digital platform as the standard for monitoring movement disorders

Apptomics is working with BBK and Biotaware to develop the remote health-monitoring platform, which recently served as a digital biomarker to evaluate treatment effects as part of an essential tremor clinical trial.

Apptomics announced Monday that its digital platform E.V.A (Evaluation. Validation. Action) has been used successfully in a study for essential tremor. Researchers used the platform as an “exploratory digital biomarker” in addition to standard clinical scales to evaluate treatment effects.

Read More
August 8, 2016

Founder and CEO Georgia Mitsi Appears on Radio Entrepreneurs to Discuss Efforts to Revolutionize the Way Patients and Physicians Manage Chronic Neurological Conditions

Host Jeffrey Davis interviews Dr. Mitsi regarding the company’s scientifically validated software solutions for people who suffer from chronic neurological conditions, such as Parkinson’s disease, Alzheimer’s, multiple sclerosis and epilepsy. Dr. Mitsi provides insight on how the company is seeking to leverage the power of technology to fill a huge gap in the effort to optimize treatment and improve patient quality of life. Radio Entrepreneurs is a business talk show that shares the inspiring stories of successful entrepreneurs.

View Now Listen to the Complete Interview
JUNE 28, 2016

BBK Worldwide, Apptomics Partner to Deliver Comprehensive Remote Health Monitoring Solutions Designed to Optimize Neurological Care

BBK Worldwide, an industry leader in patient recruitment and engagement technologies and services, is partnering with Apptomics, a provider of digital health solutions for patients living with chronic neurological conditions, to develop a new suite of mobile apps for patients, caregivers, physicians and payers. The first digital health solution, iMotor, measures and monitors motor performance for patients with Parkinson’s disease and will be utilized in a randomized Parkinson’s study later this year. Also under the new agreement, BBK Worldwide will assume a minority stake in the company and BBK Principal Matthew Stumm has been appointed to Apptomics’ board of directors. Additional terms were not disclosed. BBK is at DIA 2016 this week in Philadelphia at booth #1610 to discuss the new partnership and demo its suite of mHealth and patient recruitment and engagement solutions.

Read More
JUNE 13, 2016

Apptomics Shares Leadership Perspective on Patient-Centric mHealth Solutions for Optimized Neurological Care at Key Industry Events

Apptomics, Inc., an innovator of digital solutions for optimized neurological care, will participate in two key events this month: mHealth for Clinical Trials 2016 and the 20th Annual International Congress of Parkinson’s Disease and Movement Disorders.

Read More